Hubbry Logo
CD4+/CD8+ ratioCD4+/CD8+ ratioMain
Open search
CD4+/CD8+ ratio
Community hub
CD4+/CD8+ ratio
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
CD4+/CD8+ ratio
CD4+/CD8+ ratio
CD4+/CD8+ ratio
View on Wikipedia
from Wikipedia

The CD4+/CD8+ ratio is the ratio of T helper cells (with the surface marker CD4) to cytotoxic T cells (with the surface marker CD8). Both CD4+ and CD8+ T cells contain several subsets.[1]

The CD4+/CD8+ ratio in the peripheral blood of healthy adults and mice is about 2:1, and an altered ratio can indicate diseases relating to immunodeficiency or autoimmunity.[2] An inverted CD4+/CD8+ ratio (namely, less than 1/1) indicates an impaired immune system.[3][4][5] Conversely, an increased CD4+/CD8+ ratio corresponds to increased immune function.[6]

Obesity and dysregulated lipid metabolism in the liver leads to loss of CD4+, but not CD8+ cells, contributing to the induction of liver cancer.[7] Regulatory CD4+ cells decline with expanding visceral fat, whereas CD8+ T-cells increase.[8]

Decreased ratio with infection

[edit]

A reduced CD4+/CD8+ ratio is associated with reduced resistance to infection.[9]

Patients with tuberculosis show a reduced CD4+/CD8+ ratio.[9]

HIV infection leads to low levels of CD4+ T cells (lowering the CD4+/CD8+ ratio) through a number of mechanisms, including killing of infected CD4+. Acquired immunodeficiency syndrome (AIDS) is (by one definition) a CD4+ T cell count below 200 cells per μL. HIV progresses with declining numbers of CD4+ and expanding number of CD8+ cells (especially CD8+ memory cells), resulting in high morbidity and mortality.[10] When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.[3][4][5] Declining CD4+/CD8+ ratio has been found to be a prognostic marker of HIV disease progression.[11]

COVID-19

[edit]

In COVID-19 B cell, natural killer cell, and total lymphocyte counts decline, but both CD4+ and CD8+ cells decline to a far greater extent.[12] Low CD4+ predicted greater likelihood of intensive care unit admission, and CD4+ cell count was the only parameter that predicted length of time for viral RNA clearance.[12]

Decreased ratio with aging

[edit]

A declining CD4+/CD8+ ratio is associated with ageing, and is an indicator of immunosenescence.[5][13] Compared to CD4+ T-cells, CD8+ T-cells show a greater increase in adipose tissue in obesity and aging, thereby reducing the CD4+/CD8+ ratio.[13] Amplication of numbers of CD8+ cells are required for adipose tissue inflammation and macrophage infiltration, whereas numbers of CD4+ cells are reduced under those conditions.[14][15] Antibodies against CD8+ T-cells reduces inflammation associated with diet-induced obesity, indicating that CD8+ T-cells are an important cause of the inflammation.[15] CD8+ cell recruitment of macrophages into adipose tissue can initiate a vicious cycle of further recruitment of both cell types.[15]

Elderly persons commonly have a CD4+/CD8+ ratio less than one.[11] Obesity is associated with a reduced CD4+/CD8+ ratio,[16] and obesity tends to increase with age. A study of Swedish elderly found that a CD4+/CD8+ ratio less than one was associated with short-term likelihood of death.[11]

Immunological aging is characterized by low proportions of naive CD8+ cells and high numbers of memory CD8+ cells,[5][17] particularly when cytomegalovirus is present.[5] Exercise can reduce or reverse this effect, when not done at extreme intensity and duration.[5]

Both effector helper T cells (Th1 and Th2) and regulatory T cells (Treg) cells have a CD4 surface marker, such that although total CD4+ T cells decrease with age, the relative percent of CD4+ T cells increases.[18] The increase in Treg with age results in suppressed immune response to infection, vaccination, and cancer, without suppressing the chronic inflammation associated with aging.[18]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

CD4+/CD8+ ratio

View on Grokipedia
from Grokipedia
The CD4+/CD8+ ratio refers to the proportion of CD4-positive T lymphocytes, which primarily function as helper T cells to coordinate immune responses against infections, to CD8-positive T lymphocytes, which act as cytotoxic T cells to directly kill infected or cancerous cells, as measured in peripheral blood samples. In healthy adults, this ratio typically ranges from 1.0 to 3.0, reflecting a balanced immune system where CD4 counts are generally higher than CD8 counts. This ratio serves as a critical biomarker for assessing overall immune function, with deviations often indicating underlying immunological imbalances. A normal range is maintained through steady production and turnover of these T-cell subsets in the thymus and lymphoid tissues, but factors such as aging or chronic infections can invert the ratio (e.g., below 1.0), signaling potential immune dysregulation. In clinical practice, the ratio is calculated alongside absolute CD4 and CD8 counts from flow cytometry analysis of blood, providing a more comprehensive view than CD4 count alone, especially when CD8 levels are elevated. The ratio's significance is most prominently established in the context of human immunodeficiency virus (HIV) infection, where progressive CD4+ T-cell depletion by the virus leads to a declining ratio, correlating with increased susceptibility to opportunistic infections and progression to acquired immunodeficiency syndrome (AIDS). Antiretroviral therapy aims to restore the ratio toward normal levels, with a value above 1.0 often indicating effective immune reconstitution and reduced morbidity risk. Beyond HIV, an inverted ratio has prognostic value in other conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, where ratios below 1.0 have been associated with worse outcomes in some studies, and in aging populations, where it reflects immunosenescence and heightened inflammation. Emerging research also explores its utility in monitoring responses to immunotherapies and vaccines, underscoring its role as a versatile indicator of T-cell homeostasis.

Fundamentals

Definition

The CD4+ T cells, also known as helper T cells, are a subset of T lymphocytes that play a central role in orchestrating adaptive immune responses. These cells recognize antigens presented by major histocompatibility complex (MHC) class II molecules on antigen-presenting cells and subsequently secrete cytokines such as interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) to promote the proliferation and differentiation of other immune cells. Additionally, CD4+ T cells coordinate with B cells by providing signals through CD40 ligand and cytokines like IL-4 to facilitate B cell activation, antibody production, and class switching, while also activating macrophages via IFN-γ to enhance their ability to eliminate intracellular pathogens. In contrast, CD8+ T cells, or cytotoxic T cells, function primarily to directly eliminate infected or malignant cells. Upon recognizing antigens presented by MHC class I molecules, these cells release cytotoxic granules containing perforin, which forms pores in the target cell membrane, and granzymes, serine proteases that enter through these pores to activate caspases and induce apoptosis via DNA fragmentation and other pathways. This mechanism allows a single CD8+ T cell to serially kill multiple target cells with high specificity, sparing uninfected neighbors. The CD4+/CD8+ ratio represents the proportion of CD4+ to CD8+ T lymphocytes circulating in peripheral blood, serving as a key marker of immune balance and T cell homeostasis. It is typically calculated by dividing the absolute CD4+ T cell count by the absolute CD8+ T cell count, providing insight into the relative abundance of helper versus cytotoxic T cell populations. This ratio gained prominence in the 1980s through early HIV/AIDS research, where an inversion (below 1) was observed in initial case reports of patients with opportunistic infections and profound lymphopenia, highlighting its utility in monitoring immune status before the virus was identified.

Normal Range

In healthy adults, the CD4+/CD8+ ratio typically ranges from 1.5 to 2.5, or equivalently 1:1 to 3:1, derived from absolute lymphocyte counts measured via flow cytometry. This ratio reflects the balance between helper T cells (CD4+) and cytotoxic T cells (CD8+), with normal absolute CD4+ counts of 500 to 1200 cells/mm³ and CD8+ counts of 150 to 1000 cells/mm³. The ratio is calculated as the quotient of these absolute counts, providing a key indicator of immune homeostasis in the absence of disease. Age influences the normal range, with higher ratios observed in children—often up to 3.0 in infants and young children—due to a predominance of CD4+ cells early in life, which stabilizes around 1.5 to 2.5 in adulthood. A slight decline occurs post-60 years, with ratios potentially inverting (below 1.0) in 15-20% of older adults, reflecting age-related immune remodeling. These variations are established through population-based flow cytometry studies in healthy cohorts. Minor sex and ethnic differences exist, with ratios slightly lower in males (e.g., averaging 1.55) compared to females (averaging 1.7), attributed to hormonal influences on T-cell distribution. Among ethnic groups, individuals of African or Asian descent may exhibit modestly lower ratios (e.g., 1.2-1.5 on average) than those of European descent, linked to baseline lymphocyte subset variations, though these remain within the broad normal spectrum. Such differences are documented in large-scale reference range studies across diverse healthy populations. The ratio is often expressed relative to total T lymphocytes, where CD4+ cells constitute 30-60% and CD8+ cells 20-40% of T cells in healthy adults, derived from percentage gating in flow cytometry panels. Absolute counts are preferred for ratio computation to account for overall lymphopenia or lymphocytosis, ensuring accuracy in clinical reference intervals.

Biological Role

The maintenance of a balanced CD4+/CD8+ ratio is essential for the proper functioning of adaptive immunity, as CD4+ T cells act as helper cells that coordinate humoral immunity through B-cell activation and antibody production, while also supporting cellular immunity by enhancing macrophage and CD8+ T-cell responses. In contrast, CD8+ T cells exert cytotoxic effects to directly eliminate virus-infected cells and tumor cells, preventing unchecked proliferation of pathogens or malignancies. This equilibrium prevents overdominance of cytotoxic activity, which could cause excessive tissue damage, and ensures sufficient helper support for comprehensive immune orchestration. The CD4+/CD8+ ratio in peripheral blood primarily arises from T-cell maturation in the thymus, where bipotential double-positive (CD4+CD8+) thymocytes undergo lineage commitment to become either CD4+ helper or CD8+ cytotoxic single-positive T cells. This differentiation is driven by the affinity of the T-cell receptor for self-major histocompatibility complex (MHC) molecules: moderate affinity for MHC class II directs CD4+ lineage selection, while higher affinity for MHC class I favors CD8+ commitment. Asymmetric thymocyte death during positive and negative selection processes further shapes the ratio, typically resulting in a predominance of CD4+ cells to align with the needs of helper-mediated responses. Dysregulation of the CD4+/CD8+ ratio compromises immune surveillance, with a low ratio reflecting reduced CD4+ helper function that impairs coordination of effector responses and favors pathogen persistence due to inadequate support for cytotoxic and humoral arms. Conversely, an elevated ratio signals overactive CD4+ helper activity, which can drive excessive T-cell proliferation and cytokine production, promoting auto-reactivity and loss of self-tolerance. These imbalances highlight the ratio's role as an indicator of overall T-cell homeostasis critical for distinguishing self from non-self.

Clinical Variations

Decreased Ratio in Infections

In viral infections such as HIV, the CD4+/CD8+ ratio decreases progressively due to direct targeting and depletion of CD4+ T cells by the virus, leading to a drop below 1.0 in advanced stages of untreated disease. This depletion occurs through HIV's preferential infection of CD4+ T cells, causing their lysis and apoptosis, while CD8+ T cells expand in response to viral antigens. In chronic HIV infection under suppressive antiretroviral therapy, the ratio often remains inverted (<1.0) due to persistent immune activation and CD8+ T-cell proliferation driven by factors like gut microbial translocation and coinfections. Acute viral infections like Epstein-Barr virus (EBV) and cytomegalovirus (CMV) also lower the ratio through transient CD8+ lymphocytosis, often inverting it to below 1.0 as the immune system mounts a cytotoxic response. In acute EBV infection causing infectious mononucleosis, the massive expansion of EBV-specific CD8+ T cells—sometimes comprising over 50% of circulating lymphocytes—results in a decreased ratio, with severe cases showing means as low as 0.6 compared to 1.4 in mild cases. Similarly, subclinical CMV replication during early HIV infection or in isolation promotes CD8+ T-cell expansion without significantly affecting CD4+ counts, leading to a persistently lower ratio during treatment. Mechanistically, the decreased ratio in these infections arises from CD4+ T-cell apoptosis induced by cytokine storms and viral proteins, alongside robust CD8+ T-cell proliferation to provide cytotoxicity against infected cells. In HIV, chronic inflammation exacerbates CD4+ loss via immune dysregulation, including senescence and exhaustion markers on T cells, while CD8+ expansion reflects ongoing antiviral efforts. For EBV and CMV, the CD8+ response is antigen-driven, with cross-reactive T-cell repertoires amplifying proliferation and contributing to temporary inversion. A CD4+/CD8+ ratio below 0.5 serves as a prognostic marker of severe immunosuppression in infections like HIV, indicating higher risks of morbidity, mortality, and non-AIDS events such as cardiovascular disease, and it guides decisions on initiating or intensifying antiviral therapy. In virologically suppressed HIV patients, ratios under 0.5 correlate with larger viral reservoirs and poorer immune recovery, underscoring its value beyond CD4+ counts alone.

Decreased Ratio in Aging

The CD4+/CD8+ ratio undergoes a progressive decline with advancing age as part of immunosenescence, shifting from approximately 2:1 in young adults to 0.8-1.2 or lower by age 70 and beyond. This age-related inversion, observed in up to 16% of individuals over 60, reflects a disproportionate expansion of CD8+ T cells relative to CD4+ T cells. In cohorts of older adults (aged 65-98), ratios below 1.4 are common in about 35% of cases, correlating with reduced thymic output and altered T-cell homeostasis. Key mechanisms driving this decline include thymic atrophy, which diminishes the production of naive T cells, particularly affecting CD4+ output due to impaired thymopoiesis and reduced recent thymic emigrants. Additionally, chronic antigen exposure from persistent infections like cytomegalovirus (CMV) promotes the accumulation of CD8+ memory and effector T cells, leading to their oligoclonal expansion and further skewing the ratio. This is compounded by the depletion of naive CD4+ T cells and increased cellular senescence, exacerbated by oxidative stress and lower thymic T-cell receptor excision circle levels. The decreased ratio contributes to heightened susceptibility to infections and diminished vaccine responses in older adults, as the contracted naive T-cell pool impairs adaptive immunity to novel pathogens. It is also associated with inflammaging, a state of chronic low-grade inflammation driven by senescent CD8+ T cells secreting pro-inflammatory cytokines like IL-6 and TNF, which promotes age-related comorbidities. Emerging interventions target this imbalance through interleukin-7 (IL-7) therapy, which supports T-cell homeostasis by enhancing naive CD4+ proliferation and survival while counteracting thymic involution. Preclinical and early clinical studies in models of immunosenescence demonstrate IL-7's potential to broaden T-cell repertoire diversity and restore CD4+ counts, though it remains investigational and not yet standard for aging-related applications.

Increased Ratio in Autoimmunity

In autoimmune diseases characterized by CD4+ T cell overactivation, such as rheumatoid arthritis (RA) and multiple sclerosis (MS), the CD4+/CD8+ ratio is frequently elevated, often exceeding the normal range of approximately 1-3, due to the preferential expansion of autoreactive CD4+ T cells. In RA, peripheral blood analyses reveal significantly higher CD4+/CD8+ ratios compared to healthy controls or osteoarthritis patients, reflecting the accumulation of CD4+ effector cells in inflamed joints. Similarly, in MS, the ratio increases owing to a relative deficiency in CD8+ effector memory T cells, contributing to unchecked CD4+-mediated neuroinflammation. These shifts highlight how dysregulated CD4+ responses disrupt immune homeostasis, promoting persistent autoimmunity. The mechanisms underlying this elevated ratio involve dysregulated subsets of CD4+ T cells, particularly Th1 and Th17 cells, which drive pro-inflammatory cytokine production and tissue damage, coupled with relative suppression or reduced expansion of CD8+ T cells. Th1 cells, producing IFN-γ, and Th17 cells, secreting IL-17, amplify autoimmune inflammation in conditions like RA and MS by promoting macrophage activation and neutrophil recruitment, while CD8+ cytotoxic functions may be impaired by chronic antigenic stimulation or regulatory factors. This imbalance favors CD4+-dominant responses, exacerbating disease pathology without adequate CD8+-mediated control. Elevated CD4+/CD8+ ratios serve as a biomarker correlating with disease activity and progression in autoimmunity. In RA, an abnormal increase in the ratio during active phases predicts joint damage and therapeutic response, with dynamic changes in CD4+ and CD8+ subsets indicating flare risk. Although patterns vary across diseases, such as more variable ratios in systemic lupus erythematosus (SLE), monitoring helps track immune dysregulation overall. Therapeutic interventions targeting CD4+-driven processes can modulate the ratio toward normalization. Rituximab, a monoclonal antibody depleting CD20+ B cells that support autoreactive CD4+ activity, induces substantial CD4+ T cell reduction in RA patients, correlating with clinical improvement. This B cell-targeted approach indirectly restores T cell balance, underscoring its role in mitigating CD4+-dominant autoimmunity.

Measurement and Interpretation

Laboratory Methods

The primary method for quantifying the CD4+/CD8+ ratio in clinical settings is flow cytometry, which employs fluorescently labeled monoclonal antibodies to identify and enumerate T-cell subsets. Typically, antibodies such as anti-CD3 (to mark total T cells), anti-CD4 (for helper T cells), and anti-CD8 (for cytotoxic T cells) are used, often in combination with anti-CD45 for lymphocyte gating to distinguish them from other leukocytes based on light scatter and fluorescence properties. This single-platform approach, recommended by the Centers for Disease Control and Prevention (CDC), allows for direct measurement of absolute cell counts by incorporating reference beads into the sample, minimizing errors from separate hematology analyzers. Sample collection involves peripheral blood drawn into tubes containing K3EDTA anticoagulant to prevent clotting while preserving cell integrity, with a typical volume of 3-5 mL sufficient for analysis. Specimens must be maintained at room temperature (18-22°C) during transport and processed promptly, ideally within 48 hours of collection, as delays beyond this can lead to artifactual decreases in CD4+ counts due to cell degradation or apoptosis. Analysis should occur within 24 hours of staining to ensure accuracy, with heparin or ACD as acceptable alternatives if EDTA is unavailable. Modern flow cytometers automate absolute counting through bead-based calibration, where known quantities of fluorescent microspheres are added to the stained sample; the instrument ratios the number of gated CD4+ or CD8+ events to bead events, adjusted for sample volume, to yield counts in cells per microliter (μL). The CD4+/CD8+ ratio is then calculated as the absolute CD4+ count divided by the absolute CD8+ count: Ratio=CD4+ cells/μLCD8+ cells/μL\text{Ratio} = \frac{\text{CD4}^+ \text{ cells}/\mu\text{L}}{\text{CD8}^+ \text{ cells}/\mu\text{L}} This method enhances precision by acquiring at least 2,500 lymphocyte events per sample. Quality control adheres to standardized protocols from the CDC and World Health Organization (WHO) for HIV monitoring, including daily instrument calibration with fluorescent beads to verify optical alignment, fluorescence compensation, and light-scatter standardization. Laboratories must use stabilized reference cells or commercial controls to monitor intra- and inter-assay precision, with proficiency testing required to maintain accreditation. These measures achieve inter-laboratory variability typically below 10% for absolute CD4+ counts when using approved single-platform kits.

Clinical Implications

The CD4+/CD8+ ratio serves as a key biomarker in monitoring HIV progression and guiding antiretroviral therapy (ART) initiation, particularly when the ratio falls below 1, indicating immune dysregulation and heightened risk of opportunistic infections even in patients with normalized CD4+ counts. For instance, ratios persistently below 0.3 are linked to increased morbidity from non-AIDS events, such as cardiovascular complications, prompting earlier or intensified ART to mitigate risks. In clinical practice, a low ratio (<1) despite viral suppression signals ongoing T-cell imbalance, influencing decisions on prophylaxis for opportunistic infections and long-term immune recovery assessment. Beyond HIV, the ratio informs outcomes in solid organ transplantation, where a decreased CD4+/CD8+ ratio in allograft tissue or peripheral blood correlates with acute rejection episodes, reflecting heightened cytotoxic CD8+ activity against the graft. In cancer immunotherapy, such as with immune checkpoint inhibitors, elevated intratumoral CD8+ T-cell infiltration relative to CD4+ cells (yielding a low ratio) predicts better response and efficacy, as CD8+ effectors drive antitumor cytotoxicity. These applications highlight the ratio's role in prognostic stratification across immune-mediated conditions. Despite its utility, the CD4+/CD8+ ratio should not be interpreted in isolation; it must be integrated with absolute CD4+ counts, total lymphocyte numbers, and viral load measurements to avoid misdiagnosis, as isolated low ratios may overestimate risk in stable patients. Transient decreases can also arise from non-pathologic factors, including recent acute stress or strenuous exercise, which elevate CD8+ counts without altering CD4+ levels, potentially leading to false positives for immune compromise. Looking ahead, advancing the clinical value of the ratio involves combining it with single-cell RNA sequencing to dissect functional subsets of CD4+ and CD8+ T cells, revealing heterogeneity in exhaustion and activation states that simple ratios overlook, thus enabling personalized interventions in HIV and beyond.

References

  1. https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=167&contentid=cd4_cd8_ratio
  2. https://medlineplus.gov/lab-tests/cd4-lymphocyte-count/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC440627/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4486418/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5667733/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4981213/
  7. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.643299/full
  8. https://www.ncbi.nlm.nih.gov/books/NBK26827/
  9. https://www.ncbi.nlm.nih.gov/books/NBK27101/
  10. https://www.aidsmap.com/about-hiv/cd4cd8-ratio
  11. https://i-base.info/htb/24837
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC4271194/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC6739976/
  14. https://pubmed.ncbi.nlm.nih.gov/22067371/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC4785819/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3827884/
  17. https://i-base.info/ttfa/section-1/9-interpreting-cd4-results-cd4-count-and-cd4-percentage/
  18. https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.10011
  19. https://www.annualreviews.org/doi/10.1146/annurev-immunol-042617-053411
  20. https://www.nature.com/articles/s41467-020-20306-w
  21. https://www.sciencedirect.com/science/article/pii/S0165242720301525
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC8902567/
  23. https://journals.asm.org/doi/10.1128/mbio.01841-17
  24. https://academic.oup.com/cid/article/63/11/1517/2526242
  25. https://pubmed.ncbi.nlm.nih.gov/38361925/
  26. https://www.sciencedirect.com/science/article/pii/S0008874915001094
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8202849/
  28. https://immunityageing.biomedcentral.com/articles/10.1186/s12979-020-0173-8
  29. https://www.nature.com/articles/s41392-023-01451-2
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC5397725/
  31. https://www.nature.com/articles/s12276-025-01527-9
  32. https://pubmed.ncbi.nlm.nih.gov/18392953/
  33. https://pubmed.ncbi.nlm.nih.gov/7743743/
  34. https://journals.sagepub.com/doi/10.1177/1352458514536252
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2376206/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4137509/
  37. https://www.nature.com/articles/s41392-023-01471-y
  38. https://pubmed.ncbi.nlm.nih.gov/10941806/
  39. https://pubmed.ncbi.nlm.nih.gov/23918413/
  40. https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-016-1152-5
  41. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5202a1.htm
  42. https://www.cdc.gov/Mmwr/preview/mmwrhtml/00019952.htm
  43. https://www.labcorp.com/tests/505271/cd4-cd8-ratio-profile
  44. https://journals.asm.org/doi/10.1128/cdli.7.3.336-343.2000
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3086643/
  46. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00339-0/fulltext
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC10906605/
  48. https://onlinelibrary.wiley.com/doi/10.1155/2012/928081
  49. https://www.nature.com/articles/s41417-020-0183-x
  50. https://www.medicalnewstoday.com/articles/aids-t-cell-count
  51. https://www.nature.com/articles/s41421-021-00367-x
Add your contribution
Related Hubs
User Avatar
No comments yet.